Q: What are the key findings of the recently published secondary analysis of the STOP-NIDDM trial?
Q: 关于最近发表的STOP-NIDDM研究次级分析结果，它最重要的信息是什么？
A: The analysis of Hanefeld et al in Diabetes and Vascular Disease Research was based on the findings that acarbose reduces the risk to develop type 2 diabetes predominantly in impaired glucose tolerance (IGT) individuals in the presence of the metabolic syndrome. The number needed to treat (NNT) in the overall study population was 11， that means， 11 IGT individuals need to be treated over an average period of 3.3 years in order to prevent one case of onset of type 2 diabetes. The analysis found a clear difference between IGT individuals with metabolic syndrome， and those without metabolic syndrome: The NNT was 5.8 in IGT individuals with metabolic syndrome， and 16.5 in those without metabolic syndrome.
These findings underscore how meaningful it is to start pharmacologic diabetes prevention with Glucobay?? in those IGT individuals with concomitant metabolic syndrome and it reinforces the need to further evaluate the link between the glycaemic and cardio-vascular benefits of these substances， as is the task of the ACE study.
A: 这项次级分析是糖尿病和血管疾病研究中心的Hanefeld等在“阿卡波糖降低2型糖尿病发生风险”这一结果的基础上进行的，主要针对的是糖耐量低减（IGT）合并代谢综合征的患者。在总体研究人群中需要治疗数目（NNT）为11 ，这意味着对11例IGT患者进行为期平均3.3年以上的治疗，即可预防1例患者发生2型糖尿病。该次级分析发现在糖尿病发生风险上，合并代谢综合征的IGT患者与不合并代谢综合征的患者存在显著差异：IGT合并代谢综合征者NNT为5.8，而不合并代谢综合征者为16.5。
这些研究结果揭示，对于IGT合并代谢综合征的患者，采用抗糖尿病药物（拜唐苹）进行干预可以预防糖尿病的发生，此外还需要进一步研究以评估血糖与心血管效应之间的关系，这一点正是ACE研究的使命。